JP2023511471A - 二官能性化合物 - Google Patents

二官能性化合物 Download PDF

Info

Publication number
JP2023511471A
JP2023511471A JP2022523943A JP2022523943A JP2023511471A JP 2023511471 A JP2023511471 A JP 2023511471A JP 2022523943 A JP2022523943 A JP 2022523943A JP 2022523943 A JP2022523943 A JP 2022523943A JP 2023511471 A JP2023511471 A JP 2023511471A
Authority
JP
Japan
Prior art keywords
mmol
amino
formula
title compound
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511471A5 (cg-RX-API-DMAC7.html
Inventor
デルフィーヌ ゴーフレトー,
ロマン ヒュッター,
エレオノラ ヨフチェワ,
ベルント クーン,
トーマス ルベルス,
ライナー イー. マルティン,
レティシア ジャニン マルティン,
バルバラ ヨハナ ミュラー,
ロジャー ノークロス,
ファビエンヌ リックリン,
フィリップ シュミット,
ジャン-イヴ ワッハ,
ユルゲン ヴィヒマン,
マルティン デュプレシ,
キール ラザルスキ,
ヤンケ リャン,
Original Assignee
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
シーフォー セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト, シーフォー セラピューティクス, インコーポレイテッド filed Critical エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2023511471A publication Critical patent/JP2023511471A/ja
Publication of JP2023511471A5 publication Critical patent/JP2023511471A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022523943A 2019-10-28 2020-10-26 二官能性化合物 Pending JP2023511471A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19205545 2019-10-28
EP19205545.7 2019-10-28
PCT/US2020/057356 WO2021086785A1 (en) 2019-10-28 2020-10-26 Bifunctional compounds

Publications (2)

Publication Number Publication Date
JP2023511471A true JP2023511471A (ja) 2023-03-20
JP2023511471A5 JP2023511471A5 (cg-RX-API-DMAC7.html) 2023-10-31

Family

ID=68382246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523943A Pending JP2023511471A (ja) 2019-10-28 2020-10-26 二官能性化合物

Country Status (5)

Country Link
US (1) US20230002367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054724A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023511471A (cg-RX-API-DMAC7.html)
CN (1) CN114599428A (cg-RX-API-DMAC7.html)
WO (1) WO2021086785A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025502782A (ja) * 2021-12-28 2025-01-28 ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム がん治療剤としての強力かつ選択的なsmarca2分解キメラ分子
JP2025506452A (ja) * 2022-02-09 2025-03-11 オーリジーン オンコロジー リミテッド Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
AU2023292503A1 (en) * 2022-06-15 2024-10-31 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
CN119384414A (zh) * 2022-06-30 2025-01-28 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用
WO2024064328A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
WO2025096976A1 (en) * 2023-11-01 2025-05-08 Cornell University Arid1a is a prognostic marker for aggressive lymphoma transformation and presents a vulnerability to pharmacological inhibition of smarca4/2
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
CA3150354A1 (en) * 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
WO2021086785A1 (en) 2021-05-06
EP4054724A1 (en) 2022-09-14
US20230002367A1 (en) 2023-01-05
EP4054724A4 (en) 2023-12-27
CN114599428A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
US20230002367A1 (en) Bifunctional compounds
JP2023511472A (ja) がんの治療のための二官能性化合物
US9763922B2 (en) Therapeutic compounds and uses thereof
JP6847844B2 (ja) 治療用ピリダジン化合物およびその使用
CN107912040B (zh) 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
CN111051306A (zh) Kras g12c的抑制剂及其使用方法
CN113015724A (zh) Kras g12c抑制剂化合物的关键中间体的改善合成
JP7821808B2 (ja) がんの治療のための二環式テトラヒドロアゼピン誘導体
US20250121070A1 (en) Compounds for the targeted degradation of smarca2
WO2021178339A1 (en) Heterobifunctional molecules as tead inhibitors
TW201605857A (zh) Cdk8之醫療性抑制劑及其用途
US12110276B2 (en) Pyrazolo compounds and methods of use thereof
TW201925200A (zh) 做為tam激酶抑制劑之雙環稠合的吡啶化合物
WO2016001341A1 (en) Sulfonylaminopyridine compounds, compositions and methods of use
EP4013756B1 (en) Mll1 inhibitors and anti-cancer agents
EP4308573B1 (en) Cyclic compounds and methods of using same
HK40068906A (en) Bifunctional compounds
HK40127987A (en) Cyclic compounds and methods of using same
JP2025526683A (ja) 二環式テトラヒドロチアゼピン誘導体
JP2025526727A (ja) 二環式テトラヒドロチアゼピン誘導体

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617